Nanobiotix S.A.NBTX stock score: 48/100
$27.32 · +1.54% · Scored Nov 19, 2026
- Technical
- 43
- Fundamental
- 50
- News
- —
The reading
Nanobiotix (NBTX) scores 48 out of 100, which reads weak, higher than 43% of Healthcare stocks and 41% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 50, technicals 43.
Among the fundamentals, Price Target at 100 and Revenue Growth (Quarterly) at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 30 and contrarian oscillators 62 — a split worth reading before trusting the technical total.
Since Aug 23, 2026 the composite has ranged from 39 to 54, and it is down 5 points over the period.
About Nanobiotix
Nanobiotix (NBTX) is a France-based biotechnology company developing nanoparticle treatments that make radiation therapy more effective against cancer. Its lead product candidate, NBTXR3, is made of hafnium oxide nanoparticles injected directly into a tumor, where they absorb radiation and increase the energy delivered to cancer cells without raising the dose to surrounding healthy tissue. Johnson & Johnson holds a worldwide license to the product and sponsors a late-stage trial in elderly patients with head and neck cancer who cannot receive standard chemotherapy, along with trials in lung cancer and other tumors. The company earns revenue from the J&J agreement, including milestone payments and the supply of product, and could receive royalties if the product is approved. Its shares trade in Paris, and American depositary shares trade on Nasdaq.
Nanobiotix competes with other ways of improving radiotherapy outcomes, including chemotherapy and immunotherapy combinations and newer radiosensitizing drugs in development. Its edge rests on a physical mode of action that could apply to many tumor types treated with radiation and on a large partner funding late-stage development. Investors who follow NBTX stock tend to watch progress in the late-stage head and neck cancer trial run by J&J. Data from lung cancer and immunotherapy combination studies are closely followed. Milestone payments, cash runway and changes to the partnership terms are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward NBTX’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
50Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Year-over-year revenue growth for each of the last four quarters, weighted toward the latest.
Gross margins show profitability after cost of goods sold.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
EV/Revenue compares the whole company's value, debt included, with its sales.
30 weighted scorers; 9 had no data today and are left out rather than counted as zero.
Technical · daily
32Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
The price change over the last 52 weeks.
Williams %R (7-period) places the close within the last 7 periods' high-low range.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 35 | 1 |
| Daily | 32 | 3 |
| Weekly | 45 | 2 |
| Monthly | 61 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 20, 2026 | 48 |
| Nov 18, 2026 | 48 |
| Nov 15, 2026 | 50 |
| Nov 14, 2026 | 50 |
| Nov 13, 2026 | 49 |
| Nov 12, 2026 | 50 |
| Nov 11, 2026 | 51 |
| Nov 7, 2026 | 47 |
| Nov 6, 2026 | 47 |
| Nov 5, 2026 | 47 |
| Nov 4, 2026 | 46 |
| Nov 2, 2026 | 46 |
| Nov 1, 2026 | 48 |
| Oct 30, 2026 | 48 |
| Oct 29, 2026 | 51 |
| Oct 27, 2026 | 52 |
| Oct 26, 2026 | 49 |
| Oct 25, 2026 | 47 |
| Oct 24, 2026 | 47 |
| Oct 23, 2026 | 47 |
| Oct 22, 2026 | 44 |
| Oct 20, 2026 | 42 |
| Oct 19, 2026 | 39 |
| Oct 18, 2026 | 39 |
| Oct 17, 2026 | 39 |
| Oct 16, 2026 | 39 |
| Oct 15, 2026 | 40 |
| Oct 14, 2026 | 39 |
| Oct 13, 2026 | 39 |
| Oct 12, 2026 | 40 |
| Oct 11, 2026 | 41 |
| Oct 10, 2026 | 41 |
| Oct 9, 2026 | 41 |
| Oct 8, 2026 | 41 |
| Oct 6, 2026 | 42 |
| Oct 5, 2026 | 41 |
| Oct 4, 2026 | 41 |
| Oct 3, 2026 | 41 |
| Oct 2, 2026 | 42 |
| Oct 1, 2026 | 42 |
| Sep 30, 2026 | 44 |
| Sep 29, 2026 | 44 |
| Sep 28, 2026 | 45 |
| Sep 27, 2026 | 46 |
| Sep 26, 2026 | 46 |
| Sep 25, 2026 | 46 |
| Sep 24, 2026 | 46 |
| Sep 23, 2026 | 49 |
| Sep 22, 2026 | 47 |
| Sep 21, 2026 | 46 |
| Sep 20, 2026 | 46 |
| Sep 19, 2026 | 46 |
| Sep 18, 2026 | 45 |
| Sep 17, 2026 | 47 |
| Sep 16, 2026 | 45 |
| Sep 15, 2026 | 46 |
| Sep 14, 2026 | 46 |
| Sep 13, 2026 | 48 |
| Sep 12, 2026 | 48 |
| Sep 11, 2026 | 48 |
| Sep 10, 2026 | 48 |
| Sep 9, 2026 | 47 |
| Sep 8, 2026 | 50 |
| Sep 7, 2026 | 49 |
| Sep 6, 2026 | 49 |
| Sep 5, 2026 | 49 |
| Sep 4, 2026 | 50 |
| Sep 2, 2026 | 53 |
| Sep 1, 2026 | 51 |
| Aug 31, 2026 | 51 |
| Aug 30, 2026 | 52 |
| Aug 29, 2026 | 52 |
| Aug 28, 2026 | 52 |
| Aug 27, 2026 | 54 |
| Aug 25, 2026 | 50 |
| Aug 23, 2026 | 53 |
Key facts
- Market cap
- $1.4B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 0.54
- Risk grade (1–10)
- —
- Next earnings
- Sep 29, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| QURE uniQure | $1.4B | 45 |
| ABSI Absci | $1.4B | 27 |
| ANAB AnaptysBio | $1.4B | 69 |
| RAPP Rapport Therapeutics | $1.4B | 32 |
| IMCR Immunocore Holdings | $1.4B | 51 |
| TYRA Tyra Biosciences | $1.4B | 31 |
Questions
What is NBTX's stock rating today?
NBTX scores 48/100 (Weak) as of Nov 19, 2026: technical 43, fundamental 50. Scores are recomputed every night.
What does Nanobiotix do?
Nanobiotix (NBTX) is a France-based biotechnology company developing nanoparticle treatments that make radiation therapy more effective against cancer. Its lead product candidate, NBTXR3, is made of hafnium oxide nanoparticles injected directly into a tumor, where they absorb radiation and increase the energy delivered to cancer cells without raising the dose to surrounding healthy tissue.
Is NBTX stock a buy?
The score is not a buy or sell recommendation. A 48 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the NBTX score calculated?
92 weighted scorers feed it today: 30 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/nbtx/"><img src="https://stocksscores.com/stocks/nbtx/badge.svg" alt="NBTX stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/nbtx/)